Clinical Trials Directory

Trials / Terminated

TerminatedNCT01970527

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

RADVAX: A Stratified Phase II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
23 (actual)
Sponsor
University of Washington · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase II trial studies how well stereotactic body radiotherapy and ipilimumab work in treating patients with stage IV melanoma. Stereotactic body radiotherapy (SBRT) may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Monoclonal antibodies, such as ipilimumab, target certain cells to interfere with the ability of tumor cells to grow and spread. Giving SBRT with ipilimumab may kill more tumor cells.

Detailed description

PRIMARY OBJECTIVES: I. To determine feasibility and immune-related clinical responses associated with SBRT when given in conjunction with ipilimumab. SECONDARY OBJECTIVES: I. To determine late toxicity and immune pharmacodynamic changes after SBRT followed by ipilimumab. OUTLINE: Patients undergo a total of 3 fractions of stereotactic body radiotherapy between days 1-13. Patients then receive ipilimumab intravenously (IV) every 3 weeks. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up within 60 days, and then every effort will be made to obtain records of patients during this follow up, and permission will be sought for the investigators and/or study team to re-contact the patient directly with regard to health status and toxicity.

Conditions

Interventions

TypeNameDescription
BIOLOGICALIpilimumabGiven IV
OTHERLaboratory Biomarker AnalysisCorrelative studies
OTHERPharmacological StudyCorrelative studies
RADIATIONStereotactic Body Radiation TherapyUndergo SBRT

Timeline

Start date
2014-03-01
Primary completion
2018-11-03
Completion
2019-06-21
First posted
2013-10-28
Last updated
2020-02-13
Results posted
2020-02-13

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01970527. Inclusion in this directory is not an endorsement.

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma (NCT01970527) · Clinical Trials Directory